FLT

The fms-like tyrosine kinase (Fit) is a transmembrane receptor in the tyrosine kinase family. Expression of fit complementary DNA in COS cells conferred specific, high-affinity binding of vascular endothelial growth factor, also known as vascular permeability factor (VEGF-VPF).

Cat. No.	Product name	CAS No.	Purity
T4349	Sitravatinib	1123837-84-2	99.74%
T4349	Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
T7007	UNC2025	1429881-91-3	99.74%
T7007	UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl...
T8482	Ripretinib	1442472-39-0	99.72%
T8482	Ripretinib (DCC-2618) is an orally bioavailable inhibitor of KIT and PDGFRA.
T4419	UNC2025 2HCl (1429881-91-3(free base))	T4419	99.71%
T4419	UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
T8326	BMS-2	888719-03-7	99.7%
T8326	BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
T71857	GTP-14564	34823-86-4	99.69%
T71857	GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3. GTP-14564 inhibits the growth of interleukin-3-independent Ba/F1 expressi...
T6711	Tyrphostin AG1296	146535-11-7	99.68%
T6711	Tyrphostin AG1296 (Tyrphostin AG 1296) is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
T3166	VX-11e	896720-20-0	99.67%
T3166	VX-11e (TCS ERK 11e) is a potent, selective, and orally bioavailable ERK(Extracellular Signal-Regulated Kinase) inhibitor; antitumor agent.
T2115	Pexidartinib	1029044-16-3	99.66%
T2115	Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antin...
T6289	Dovitinib	405169-16-6	99.66%
T6289	Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) an...
T9017	HPK1-IN-2	2056122-11-1	99.62%
T9017	HPK1-IN-2 (Thieno[2,3-b]pyridin-6(7H)-one, 4-amino-5-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-HPK1-IN-2) is a potent and orally active inhibitor of hema...
T9027	CA-4948	1801344-14-8	99.62%
T9027	CA-4948 (Emavusertib) is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
T0093L	Sorafenib	284461-73-0	99.61%
T0093L	Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/...
T9856	FLT3-IN-10	2088735-51-5	99.60%
T9856	FLT3-IN-10 (2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl-) (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 shows the potential...
T2586	Cabozantinib	849217-68-1	99.59%
T2586	Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Caboz...
T4213	NCT-503	1916571-90-8	99.56%
T4213	NCT-503 is an inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), inhibiting serine synthesis from 3-phosphoglycerate in cells.
T27011	CHMFL-FLT3-122	1839150-56-9	99.56%
T27011	CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia. CHMFL-FLT3-122 significantly suppre...
T3455	Merestinib	1206799-15-6	99.56%
T3455	Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib...
T6080	NVP-AEW541	475489-16-8	99.55%
T6080	NVP-AEW541 (AEW541), a potent inhibitor of IGF-1R(IC50=150 nM) and InsR(IC50=140 nM), exhibits excellent efficiency and specificity for IGF-1R in a cell-based as...
T5466	Tyrosine kinase-IN-1	705946-27-6	99.55%
T5466	Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor（KDR, Flt-1, FGFR1 and PDGFRα with IC50s of 4nM, 20nM, 4nM, 2 nM ,respectively）